Kymera Perspectives

From Target Selection to POC in Patients: Completing the Initial Human Translation of STAT6 Degradation

Since we disclosed our STAT6 program, we have demonstrated that KT-621, our first-in-class oral STAT6 degrader and the first STAT6-targeted agent in clinical development, can block the IL-4/IL-13 pathway completely and at least as robustly as an upstream biologic like dupilumab. We have shown this in preclinical studies, in healthy volunteers, and now in patients with atopic dermatitis. Hear from Nello Mainolfi, PhD, Founder, President and CEO, on how our data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world.